401 related articles for article (PubMed ID: 25925842)
1. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Koretsune Y; Yamashita T; Kimura T; Fukuzawa M; Abe K; Yasaka M
Circ J; 2015; 79(7):1486-95. PubMed ID: 25925842
[TBL] [Abstract][Full Text] [Related]
2. Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).
Suzuki S; Morishima Y; Takita A; Otsuka T; Yagi N; Arita T; Yamashita T
Heart Vessels; 2020 Mar; 35(3):409-416. PubMed ID: 31522245
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment.
Shimizu T; Tachibana M; Kimura T; Kumakura T; Yoshihara K
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):484-491. PubMed ID: 28032482
[TBL] [Abstract][Full Text] [Related]
4. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
[TBL] [Abstract][Full Text] [Related]
6. Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?
Ikeda T
Circ J; 2015; 79(7):1441-3. PubMed ID: 26028323
[No Abstract] [Full Text] [Related]
7. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Yamashita T; Koretsune Y; Yasaka M; Inoue H; Kawai Y; Yamaguchi T; Uchiyama S; Matsumoto M; Ogawa S
Circ J; 2012; 76(8):1840-7. PubMed ID: 22664798
[TBL] [Abstract][Full Text] [Related]
8. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
10. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
11. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
[TBL] [Abstract][Full Text] [Related]
13. Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment.
Fazio G; Dentamaro I; Gambacurta R; Alcamo P; Colonna P
Clin Drug Investig; 2018 Nov; 38(11):1023-1030. PubMed ID: 30191509
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.
Fuji T; Fujita S; Kawai Y; Abe Y; Kimura T; Fukuzawa M; Abe K; Tachibana S
Thromb J; 2015; 13(1):6. PubMed ID: 25653574
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Steffel J; Ruff CT; Yin O; Braunwald E; Park JG; Murphy SA; Connolly S; Antman EM; Giugliano RP
J Am Coll Cardiol; 2021 Mar; 77(9):1197-1207. PubMed ID: 33663737
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
[TBL] [Abstract][Full Text] [Related]
18. Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation.
Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Takahashi M; Kanbara T; Inoue Y; Nakashima Y; Asano H; Sakai K
Circ J; 2016; 80(3):745-7. PubMed ID: 26821582
[TBL] [Abstract][Full Text] [Related]
19. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
[TBL] [Abstract][Full Text] [Related]
20. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]